|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Reciprocally, overexpression of C-MYC in normal melanocytes suppressed BRAF(V600E)-induced senescence more efficiently than NRAS(Q61R)-induced senescence, which agrees with the generally higher rates of activating mutations in BRAF than NRAS gene in human cutaneous me</span>lanomas.
|
18679422 |
2008 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In our study, we showed that combining immunohistochemistry analysis targeting NRAS(Q61R) and BRAF(V600E) proteins with molecular analysis was a reliable theranostic tool to face challenging samples of melanoma.
|
26204954 |
2015 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The activating NRAS p.Q61R variant is a known "hotspot" variant, frequently identified in several types of human cancer, especially melanoma.
|
30542204 |
2019 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and NRAS 182A>G [Q61R] and 181C>A [Q61K] in melanoma, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in non-small-cell lung cancer, and compared the results to DNA sequencing of the mutation 'hot-spots' in these genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA.
|
20925915 |
2010 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here, we report that guanosine monophosphate synthase (GMPS), an enzyme required for the de novo biosynthesis of GMP, has a major role in invasion and tumorigenicity of cells derived from either BRAF(V600E) or NRAS(Q61R) human metastatic melanomas.
|
25909885 |
2015 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We observed an increase in NRAS mutant allele percentage (NRAS-MA%) in the metastatic melanoma progression from 2 patients with melanomas harbouring a NRAS mutation (p.Q61K in case 1 and p.Q61R in case 2).
|
26990546 |
2016 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We investigated the associations between BRAF(V600E) and NRAS(Q61R) mutations and known risk factors, clinicopathologic characteristics and clinical outcomes of melanoma in a case series of primary invasive cutaneous melanoma from the Nurses' Health Study (NHS).
|
25048604 |
2014 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Besides confirming the presence of known melanoma driver mutations (BRAF(V600E), NRAS(Q61R) ), we identified novel mutated genes involved in signalling pathways crucial for melanoma pathogenesis and already addressed by current targeted therapies (such as MAPK and glutamate pathways).
|
23704925 |
2013 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Genetic analysis revealed an activating NRAS Q61R mutation within the melanoma, which is more commonly associated with large or giant congenital melanocytic nevi.
|
27573553 |
2016 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Formalin-fixed and paraffin-embedded melanoma tissues were analyzed for BRAF and NRAS mutations by independent, blinded observers using both conventional DNA molecular techniques and immunohistochemistry with the novel anti-human N-Ras (Q61R) monoclonal antibody (clone SP174).
|
25341653 |
2015 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We studied global gene expression in three melanoma cell lines with the most common and potent V600E mutation in the B-RAF gene-four cell lines with a common Q61R mutation in the N-RAS gene and three cell lines with no mutations using human HG-U133A 2.0 micro-arrays with 22 277 transcripts.
|
15760917 |
2005 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The rarity of HRAS and KRAS Q61R mutants in malignant melanoma</span> let previous investigations erroneously conclude that SP174 is specific for NRAS Q61R-mutant protein.
|
29206715 |
2018 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This study thus defined SPRY4 as a potential mediator of synthetic suppression, which is likely to contribute to the observed exclusivity between BRAF(V600E) and NRAS(Q61R) mutations in melanoma.
|
30651601 |
2019 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Mutation in BRAF and NRAS was present in 43% (88% V600E, 10% V600K) and 30% (48% Q61K, 40% Q61R) of metastatic melanomas, respectively.
|
23855428 |
2013 |
|
rs11554290
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We present the clinical course, unique morphology, angiogenic properties, growth characteristics using in vivo experiments and 3D cell culture, and results of the exome gene sequencing of an intensively pigmented melanogenic cell line MUG-Mel2, derived from a cutaneous metastasis of an aggressive NRAS p. Q61R mutated melanoma.
|
28522871 |
2017 |
|
rs11554290
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
|
20179705 |
2010 |
|
rs11554290
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |
|
rs11554290
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
|
23569304 |
2013 |
|
rs11554290
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
Ras mutations in human melanoma: a marker of malignant progression.
|
8120410 |
1994 |
|
rs11554290
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
|
23414587 |
2013 |
|
rs11554290
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
NRAS-mutant melanoma: response to chemotherapy.
|
21576590 |
2011 |
|
rs11554290
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |
|
rs11554290
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
|
23538902 |
2013 |
|
rs11554290
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
Furthermore, PLX4032 increased the rate of proliferation of growth factor-dependent NRAS Q61L mutant primary melanoma cells, reduced cell adherence and increased mobility of cells from advanced lesions.
|
20149136 |
2010 |